ライフサイエンスコーパス: Bayer

1 by adding magnesium carbonate (as in Rennie, Bayer).

2 COG-ACRIN Cancer Research Group, Pfizer, and Bayer.

3 ck Sharp & Dohme (a subsidiary of Merck) and Bayer.

4 was only significantly reduced by FG4592 or Bayer 85-3934 in PC12 cells.

5 C virus genotyping methodologies supplied by Bayer, Abbott, and Third Wave Technologies.

6 Bayer AG and Janssen Research & Development.

7 Bayer AG, Janssen Research and Development.

8 Asundexian (Bayer AG, Leverkusen, Germany), an oral small molecule f

9 library of over 11,000 compounds provided by Bayer AG.

10 Bayer and Agouron have discontinued their ongoing Phase

11 Bayer and Janssen Research & Development.

12 nd incorporates branched DNA technology from Bayer and luminometer-based readings of a chemilumigenic

13 Bristol Myers Squibb, Bayer and National Institutes of Health/National Cancer

14 Abbott assay measure = 0.032 + 1.01 log(10) Bayer assay measure.

15 .0 test was slightly better than that of the Bayer bDNA 3.0 test, but the Monitor test underquantifie

16 2 log10 greater than those obtained with the Bayer bDNA assay for genotype 1, 2, and 3 samples.

17 61 to 0.96 log10 greater than the values for Bayer bDNA assay for samples with genotype 1, 2, or 3 sa

18 Roche Monitor and Bayer bDNA detected 27 out of 28 and 13 out of 28 replic

19 Bayer bDNA was the most reproducible of the four assays.

20 che Monitor), and Bayer VERSANT HCV RNA 3.0 (Bayer bDNA) assays.

21 s genotypes (1 through 4) were tested in the Bayer bDNA, Abbott RT-PCR, and Roche RT-PCR assays.

22 Bayer bDNA-negative specimens were tested reflexively us

23 n average, 0.15 log10 lower than that of the Bayer bDNA.

24 using the known transmission spectra of the Bayer color filters.

25 pixels of different channels (R, G, B) on a Bayer color sensor are not at the same physical location

26 developed to enable the use of the low-cost Bayer color sensor, to compensate for the highly aberrat

27 the imaging process by a factor of three, a Bayer color sensor-chip can also be used to demultiplex

28 Screening of the Bayer compound library led to the discovery of tetrahydr

29 ith a commercial genotyping assay (Tru Gene; Bayer Corp.) were analyzed to assess the utility of thes

30 dization line probe assay (INNO-LiPA HCV II; Bayer Corp., Tarrytown, N.Y.) for genotyping of hepatiti

31 European Union, Cancer Research UK, Bayer Corporation, National Starch and Chemical Co, UK M

32 European Union; Cancer Research UK; Bayer Corporation; National Starch and Chemical Co; UK M

33 ide urine ACR was measured by nurses using a Bayer DCA 2000 analyzer and expressed in mg/mmol (refere

34 In this concern, Bayer developed a combination of the neonicotinoid cloth

35 recision, and excellent correlation with the Bayer Diagnostics VERSANT HBV DNA 3.0 (branched DNA) ass

36 HCV RNA 2.0 branched-chain DNA (bDNA) assay (Bayer Diagnostics) for hepatitis C viral load determinat

37 ation, the VERSANT HCV RNA 3.0 Assay (bDNA) (Bayer Diagnostics, Tarrytown, N.Y.) was shown to have ex

38 th recognized by the Advia Centaur BNP test (Bayer Diagnostics, Tarrytown, New York), but only recomb

39 ell Host & Microbe, Lazear et al. (2016) and Bayer et al. (2016) show that innate immunity can restri

40 62 from the German drug authority, 536 from Bayer (extracted from the Bayer pharmacovigilance system

41 t of hepatitis C virus (HCV) RNA levels, the Bayer HCV RNA (version 3.0) branched DNA assay and the A

42 Janssen Research & Development and Bayer HealthCare AG.

43 CV and the VERSANT HCV RNA 3.0 assay (bDNA) (Bayer HealthCare LLC) among a group of 93 clinical speci

44 ive by the VERSANT HCV RNA qualitative test (Bayer HealthCare LLC, Tarrytown, N.Y.).

45 HBV ASR and VERSANT HBV DNA 3.0 assay (bDNA; Bayer HealthCare LLC, Tarrytown, NY) results among clini

46 d from the TRUGENE HCV 5' NC Genotyping Kit (Bayer HealthCare LLC, Tarrytown, NY), used in conjunctio

47 Bayer HealthCare Pharmaceuticals and Janssen Research &

48 Bayer HealthCare Pharmaceuticals and Janssen Research &

49 Bayer HealthCare Pharmaceuticals and Onyx Pharmaceutical

50 rast-enhanced (7 mL of gadobutrol, Gadavist; Bayer Healthcare Pharmaceuticals, Berlin, Germany) MRI (

51 rast-enhanced (7 mL of gadobutrol, Gadavist; Bayer Healthcare Pharmaceuticals, Berlin, Germany) MRI (

52 Algeta and Bayer HealthCare Pharmaceuticals.

53 Novo Nordisk, Bayer HealthCare, [corrected] and Pfizer.

54 VEGF Trap-Eye; Regeneron, Tarrytown, NY, and Bayer HealthCare, Berlin, Germany) with monthly ranibizu

55 1 mL per kilogram of body weight; Magnevist; Bayer Healthcare, East Mississauga, Ontario) during the

56 1 mL per kilogram of body weight; Magnevist; Bayer Healthcare, East Mississauga, Ontario) during the

57 1 mL per kilogram of body weight; Magnevist; Bayer Healthcare, East Mississauga, Ontario) during the

58 1 mL per kilogram of body weight; Magnevist; Bayer Healthcare, East Mississauga, Ontario) during the

59 (MR) imaging with gadoxetic acid (Primovist; Bayer Healthcare, Whippany, NJ) was performed.

60 Cancer Research UK, GE Healthcare, and Bayer Healthcare.

61 sted hazard ratio (HR) (95% CI) for Kogenate Bayer/Helixate NexGen compared with Advate was 2.14 (1.1

62 Of 128 patients treated with Kogenate Bayer/Helixate NexGen, 45 (35.2%, 95% confidence interva

63 Kruip: Bayer: Honoraria, Research Funding; Daiichi Sankyo: Rese

64 pared with gadobutrol (Gadovist or Gadavist, Bayer; macrocyclic GBCA) and gadodiamide (Omniscan, GE H

65 e determined for 136 of 137 specimens by the Bayer method, 121 of 137 specimens by the Invader assay,

66 nsive Clinical Trials Unit at UCL, LUPUS UK, Bayer, National Institute for Health Research Biomedical

67 The second generation Hoechst-Bayer non-nucleoside inhibitor, HBY 097 (S-4-isopropoxyc

68 National Cancer Institute, Bayer Oy (formerly Schering Oy).

69 ncer Research UK, European Union, MRC, NIHR, Bayer Pharma AG, Barbour Foundation.

70 tomatic, and gadolinium-enhanced (Magnevist; Bayer Pharma, Berlin, Germany) magnetic resonance (MR) i

71 ish Cancer Foundation, SIAK Switzerland, and Bayer Pharma.

72 Finnish Cancer Foundation; SIAK Switzerland; Bayer Pharma.

73 uthority, 536 from Bayer (extracted from the Bayer pharmacovigilance system, the WHO VigiBase, and fr

74 AMPLICOR HIV-1 MONITOR test version 1.0, the Bayer Quantiplex HIV RNA 3.0 assay, or a QC-RT-PCR metho

75 rcially available ultrasensitive assays, the Bayer Quantiplex HIV-1 bDNA version 3.0 (bDNA 3.0) assay

76 a high-throughput screening hit derived from Bayer's compound library.

77 In this issue of Cell Host & Microbe, Bayer-Santos et al. (2016) show that the Salmonella effe

78 Northern Ireland, Biogen Idec, Merck Serono, Bayer Schering Pharmaceuticals, Teva Pharmaceuticals Ind

79 3.05 million compounds originating from the Bayer screening library failed to identify any tractable

80 Bayer TMA detected all seven replicates with 1.0 log10 I

81 the Bayer VERSANT HCV RNA qualitative assay (Bayer TMA).

82 The Bayer transcription-mediated amplification (TMA) and the

83 We evaluated the Bayer TRUGENE HIV-1 genotyping (TG) assay using prospect

84 he multikinase inhibitor sorafenib (Nexavar, Bayer), used in the treatment of renal and hepatocellula

85 TaqMan Analyte-Specific Reagent (TaqMan) and Bayer Versant HCV bDNA 3.0 assay.

86 mplicor Monitor HCV 2.0 (Roche Monitor), and Bayer VERSANT HCV RNA 3.0 (Bayer bDNA) assays.

87 ell with HCV viral load as determined by the Bayer VERSANT HCV RNA 3.0 bDNA assay.

88 Stored specimens were tested using the Bayer VERSANT HCV RNA Qualitative (TMA) Assay (LOD 9.6 I

89 specimens were tested reflexively using the Bayer VERSANT HCV RNA qualitative assay (Bayer TMA).

90 Roche COBAS Amplicor and Bayer VERSANT HCV RNA qualitative assays were used.

91 was evaluated in the CAP/CTM, Amplicor, and Bayer Versant HIV-1 bDNA 3.0 (Versant) assays using a co

92 Abbott LCx HIV RNA Quantitative assay (LCx), Bayer Versant HIV-1 RNA 3.0 (bDNA), Roche AMPLICOR HIV-1

93 erally agreed with the results of the B-DNA (Bayer) viral load assays.

94 >20,000 compounds tested in Caco2 assays at Bayer, we have examined the molecular properties governi